Covaxin production slowed down, this is what Bharat Biotech will now focus on

Bharat Biotech on Friday said that it is temporarily slowing down the production of its COVID-19 vaccine Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement agencies and foresees decrease in demand.

The company further said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on more improvements and upgrades to make sure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

“For the coming period, the company will focus on pending facility maintenance, process, and facility optimisation activities,” Bharat Biotech said in a statement.